Commonalities and differences between Crohn's disease and ulcerative colitis: The genetic clues to their interpretation

Inflammation and Allergy - Drug Targets

Volumn 10, Issue 6, 2011, Pages 447-454

  Actis, Giovanni C ^a   Pellicano, Rinaldo ^b   Tarallo, Sonia ^a   Rosina, Floriano ^a  

^a GRADENIGO HOSPITAL   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Crohn's disease; Genome wide association; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

CLINICAL FEATURE; COLONOSCOPY; CROHN DISEASE; ENVIRONMENTAL FACTOR; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

EID: 81155132411     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152811798104926     Document Type: Review

References (85)

1. Rubin, G.P.; Hungin, A.P.; Kelly, P.J.; Ling, J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment. Pharmacol. Ther., 2000, 4, 1553-1559.
2. Kim, E.S.; Kim, W.H. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver, 2010, 4, 1-14.
3. Actis G.C.; Pazienza P; Rosina F. Mesalamine for inflammatory bowel disease: recent reappraisals. Inflamm. Allergy Drug Targets, 2008, 7, 1-5.
4. Baumgart, D.C.; Sandborn, W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007, 369, 1641-1657.
5. Solberg, I.C.; Vatn, M.H.; Høie, O.; Stray, N.; Sauar, J.; Jahnsen, J.; Moum, B.; Lygren, I.; IBSEN Study Group. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin. Gastroenterol. Hepatol., 2007, 5, 1430-1438.
6. Solberg, I.C.; Lygren, I.; Jahnsen, J.; Aadland, E.; Høie, O.; Cvancarova, M.; Bernklev, T.; Henriksen, M.; Sauar, J.; Vatn, M.H.; Moum, B.; IBSEN Study Group. Clinical course during the first ten years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand. J. Gastroenterol., 2009, 44, 431-440.
7. Actis, G.C.; Rosina, F. Out-patient care for inflammatory bowel disease at a primary referral hospital in Turin. Minerva Gastroenterol. Dietol., 2010, 56, 27-34.
8. Jevon, G.P.; Madhur, R. Endoscopic and histologic findings in pediatric inflammatory bowel disease. Gastroenterol. Hepatol. (NY), 2010, 6, 174-180.
9. Mazlam, M.Z.; Hodgson, H.J. Why measure C-reactive protein? Gut, 1994; 35, 5-7.
10. Henriksen, M.; Jahnsen, J.; Lygren, I.; Stray, N.; Sauar, J.; Vatn, M.H.; Moum, B.; IBSEN Study Group. C-reactive protein: a predictive factor and markers of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut, 2008, 57, 1518-1523.
11. Vermeire, S.; van Assche, G.; Rutgeerts, P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm. Bowel Dis., 2004, 10, 661-665.
12. Dotan, I. New serologic markers for inflammatory bowel disease diagnosis. Dig. Dis., 2010, 28, 418-423.
13. Hanauer, S.; Schwartz, J.; Robinson, M.; Roufail, W.; Arora, S.; Cello, J.; Safdi, M. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. PENTASA Study Group. Am. J. Gastroenterol., 1993, 88, 1188-1197.
14. Sutherland, L.; McDonald, J.K. Oral 5-ASA for maintenance of remission of ulcerative colitis. Cochrane Database Syst. Rev., 2006, 19, CD000544.
15. Ford, A.C.; Kane, S.V.; Khan, K.J.; Achkar, J.P.; Talley, N.J.; Marshall, J.K.; Moayyedi, P. Efficacy of 5-aminosalicylates in Crohn's disease:systematic review and meta-analysis. Am. J. Gastroenterol., 2011, 106, 617-629.
16. Faubion, W.A. Jr; Loftus, E.V. Jr; Harmsen, W.S.; Zinsmeister, A.R.; Sandborn, W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology, 2001, 121, 255-260.
17. Present, D.H.; Korelitz, B.I.; Wisch, N.; Glass, J.L.; Sachar, D.B.; Pasternack, B.S. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N. Engl. J. Med., 1980, 302, 981-987.
18. Cassinotti, A.; Actis, G.C.; Duca, P.; Massari, A.; Colombo, E.; Gai, E.; Annese, V.; D'Albasio, G.; Manes, G.; Travis, S.; Porro, G.B.; Ardizzone, S. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am. J. Gastroenterol., 2009, 104, 2760-2767.
19. Khan, K.J.; Ullman, T.A.; Ford, A.C.; Abreu, M.T.; Abadir, A.; Marshall, J.K.; Talley, N.J.; Moayyedi, P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol., 2011, 106, 661-673.
20. Prantera, C.; Scribano, M.L. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr. Opin. Gastroenterol., 2009, 25, 329-333.
21. Munkholm, P.; Langholz, E.; Davidsen, M.; Binder, V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut, 1994, 35, 360-362.
22. Edwards, F.C.; Truelove, S.C. The course and prognosis of ulcerative colitis. Gut, 1963, 4, 299-315.
23. Mascarell, L.; Truffa-Bachi, P. Cyclosporin A therapy differently affects immunological- relevant gene expression following immunization. Immunol. Lett., 2002, 84, 137-143.
24. Ebert, EC. Infliximab and the TNF-alpha system. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296, G612-20.
25. Actis, G.C.; Fadda, M.; David, E.; Sapino, A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterology, 2007, 7, 13.
26. Sharkey, L.; Bredin, F.; Nightingale, A.; Parkes, M. The use of cyclosporin A in acute steroid-refractory ulcerative colitis: long term outcomes. J. Crohns Colitis, 2011, 5, 91-4.
27. Lichtiger, S.; Present, D.H.; Kornbluth, A.; Gelernt, I.; Bauer, J.; Galler, G.; Michelassi, F.; Hanauer, S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med., 1994, 330, 1841-1845.
28. Rutgeerts, P.; Sandborn, W.J.; Feagan, B.G.; Reinisch, W.; Olson, A.; Johanns, J.; Travers, S.; Rachmilewitz, D.; Hanauer, S.B.; Lichtenstein, G.R.; de Villiers, W.J.; Present, D.; Sands, B.E.; Colombel, J.F. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 353, 2462-2476.
29. Gisbert, J.P.; González-Lama, Y.; Maté, J. Systematic review: infliximab therapy in ulcerative colitis. Aliment. Pharmacol. Ther., 2007, 25, 19-37.
30. Laharie, D; Bourreille, A; Branche, J. Cyclosporin versus infliximab in acute severe ulcerative colitis refractory to intravenous steroids: a randomized study. J. Crohns Colitis, 2011, 5 (S8).
31. Cheifetz, A.S.; Stern, J.; Garud, S.; Goldstein, E.; Malter, L.; Moss, A.C.; Present, D.H. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J. Clin. Gastroenterol., 2011, 45, 107-112.
32. McDonald, J.W.; Feagan, B.G.; Jewell, D.; Brynskov, J.; Stange, E.F.; Macdonald, J.K. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst. Rev., 2005, 2, CD000297.
33. Schnitzler, F.; Fidder, H.; Ferrante, M.; Noman, M.; Arijs, I.; Van Assche, G.; Hoffman, I.; Van Steen, K.; Vermeire, S.; Rutgeerts, P. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut, 2009, 58, 492-500.
34. Lees, C.W.; Barrett, J.C.; Parkes, M.; Satsangi, J. New IBD genetics: common pathways with other diseases. Gut, 2011, [Epub Ahead of Print].
35. Thompson, A.I.; Lees, C.W. Genetics of ulcerative colitis. Inflamm. Bowel Dis., 2011, 17, 831-848.
36. Orholm, M.; Binder, V.; Sørensen, T.I.; Rasmussen, L.P.; Kyvik, K.O. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand. J. Gastroenterol., 2000, 35, 1075-1081.
37. Orholm, M.; Iselius, L.; Sørensen, T.I.; Munkholm, P.; Langholz, E.; Binder, V. Investigation of inheritance of chronic inflammatory bowel diseases by complex segregation analysis. BMJ, 1993, 306, 20-24.
38. International HapMap Consortium. A haplotype map of the human genome. Nature, 2005, 437, 1299-1320.
39. de Bakker, P.I.; Ferreira, M.A.; Jia, X.; Neale, B.M.; Raychaudhuri, S.; Voight, B.F. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum. Mol. Genet., 2008, 17(R2), R122-128.
40. Anderson, C.A.; Boucher, G.; Lees, C.W.; Franke, A.; D'Amato, M.; Taylor, K.D.; Lee, J.C.; Goyette, P.; Imielinski, M.; Latiano, A.; Lagacé, C.; Scott, R.; Amininejad, L.; Bumpstead, S.; Baidoo, L.; Baldassano, R.N.; Barclay, M.; Bayless, T.M.; Brand, S.; Büning, C.; Colombel, J.F.; Denson, L.A.; De Vos, M.; Dubinsky, M.; Edwards, C.; Ellinghaus, D.; Fehrmann, R.S.; Floyd, J.A.; Florin, T.; Franchimont, D.; Franke, L.; Georges, M.; Glas, J.; Glazer, N.L.; Guthery, S.L.; Haritunians, T.; Hayward, N.K.; Hugot, J.P.; Jobin, G.; Laukens, D.; Lawrance, I.; Lémann, M.; Levine, A.; Libioulle, C.; Louis, E.; McGovern, D.P.; Milla, M.; Montgomery, G.W.; Morley, K.I.; Mowat, C.; Ng, A.; Newman, W.; Ophoff, R.A.; Papi, L.; Palmieri, O.; Peyrin-Biroulet, L.; Panés, J.; Phillips, A.; Prescott, N.J.; Proctor, D.D.; Roberts, R.; Russell, R.; Rutgeerts, P.; Sanderson, J.; Sans, M.; Schumm, P.; Seibold, F.; Sharma, Y.; Simms, L.A.; Seielstad, M.; Steinhart, A.H.; Targan, S.R.; van den Berg, L.H.; Vatn, M.; Verspage, H.; Walters, T.; Wijmenga, C.; Wilson, D.C.; Westra, H.J.; Xavier, R.J.; Zhao, Z.Z.; Ponsioen, C.Y.; Andersen, V.; Torkvist, L.; Gazouli, M.; Anagnou, N.P.; Karlsen, T.H.; Kupcinskas, L.; Sventoraityte, J.; Mansfield, J.C.; Kugathasan, S.; Silverberg, M.S.; Halfvarson, J.; Rotter, J.I.; Mathew, C.G.; Griffiths, A.M.; Gearry, R.; Ahmad, T.; Brant, S.R.; Chamaillard, M.; Satsangi, J.; Cho, J.H.; Schreiber, S.; Daly, M.J.; Barrett, J.C.; Parkes, M.; Annese, V.; Hakonarson, H.; Radford-Smith, G.; Duerr, R.H.; Vermeire, S.; Weersma, R.K.; Rioux, J.D. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet., 2011, 43, 246-252.
41. Franke, A.; McGovern, D.P.; Barrett, J.C.; Wang, K.; Radford-Smith, G.L.; Ahmad, T.; Lees, C.W.; Balschun, T.; Lee, J.; Roberts, R.; Anderson, C.A.; Bis, J.C.; Bumpstead, S.; Ellinghaus, D.; Festen, E.M.; Georges, M.; Green, T.; Haritunians, T.; Jostins, L.; Latiano, A.; Mathew, C.G.; Montgomery, G.W.; Prescott, N.J.; Raychaudhuri, S.; Rotter, J.I.; Schumm, P.; Sharma, Y.; Simms, L.A.; Taylor, K.D.; Whiteman, D.; Wijmenga, C.; Baldassano, R.N.; Barclay, M.; Bayless, T.M.; Brand, S.; Büning, C.; Cohen, A.; Colombel, J.F.; Cottone, M.; Stronati, L.; Denson, T.; De Vos, M.; D'Inca, R.; Dubinsky, M.; Edwards, C.; Florin, T.; Franchimont, D.; Gearry, R.; Glas, J.; Van Gossum, A.; Guthery, S.L.; Halfvarson, J.; Verspaget, H.W.; Hugot, J.P.; Karban, A.; Laukens, D.; Lawrance, I.; Lemann, M.; Levine, A.; Libioulle, C.; Louis, E.; Mowat, C.; Newman, W.; Panés, J.; Phillips, A.; Proctor, D.D.; Regueiro, M.; Russell, R.; Rutgeerts, P.; Sanderson, J.; Sans, M.; Seibold, F.; Steinhart, A.H.; Stokkers, P.C.; Torkvist, L.; Kullak-Ublick, G.; Wilson, D.; Walters, T.; Targan, S.R.; Brant, S.R.; Rioux, J.D.; D'Amato, M.; Weersma, R.K.; Kugathasan, S.; Griffiths, A.M.; Mansfield, J.C.; Vermeire, S.; Duerr, R.H.; Silverberg, M.S.; Satsangi, J.; Schreiber, S.; Cho, J.H.; Annese, V.; Hakonarson, H.; Daly, M.J.; Parkes, M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet., 2010, 42, 1118-25.
42. Abraham, C.; Cho, J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm. Bowel Dis., 2009, 15, 1090-100.
43. Oppmann, B.; Lesley, R.; Blom, B.; Timans, J.C.; Xu, Y.; Hunte, B.; Vega, F.; Yu, N.; Wang, J.; Singh, K.; Zonin, F.; Vaisberg, E.; Churakova, T.; Liu, M.; Gorman, D.; Wagner, J.; Zurawski, S.; Liu, Y.; Abrams, J.S.; Moore, K.W.; Rennick, D.; de Waal-Malefyt, R.; Hannum, C.; Bazan, J.F.; Kastelein, R.A. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 2000, 13, 715-725.
44. Carmody, R.J.; Ruan, Q.; Liou, H.C.; Chen, Y.H. Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. J. Immunol., 2007, 178, 186-191.
45. Khayrullina, T.; Yen, J.H.; Jing, H.; Ganea, D. In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J. Immunol., 2008, 181, 721-735.
46. Kamada, N.; Hisamatsu, T.; Okamoto, S.; Sato, T.; Matsuoka, K.; Arai, K.; Nakai, T.; Hasegawa, A.; Inoue, N.; Watanabe, N.; Akagawa, K.S.; Hibi, T. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J. Immunol., 2005, 175, 6900-6908.
47. Sugimoto, K.; Ogawa, A.; Mizoguchi, E.; Shimomura, Y.; Andoh, A.; Bhan, A.K.; Blumberg, R.S.; Xavier, R.J.; Mizoguchi, A. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest., 2008, 118, 534-544.
48. Parham, C.; Chirica, M.; Timans, J.; Vaisberg, E.; Travis, M.; Cheung, J.; Pflanz, S.; Zhang, R.; Singh, K.P.; Vega, F.; To, W.; Wagner, J.; O'Farrell, A.M.; McClanahan, T.; Zurawski, S.; Hannum, C.; Gorman, D.; Rennick, D.M.; Kastelein, R.A.; de Waal Malefyt, R.; Moore, K.W. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol., 2002, 168, 5699-5708.
49. Tesmer, L.A.; Lundy, S.K.; Sarkar, S.; Fox, D.A. Th17 cells in human disease. Immunol. Rev., 2008, 223, 87-113.
50. Becker, C.; Wirtz, S.; Blessing, M.; Pirhonen, J.; Strand, D.; Bechthold, O.; Frick, J.; Galle, P.R.; Autenrieth, I.; Neurath, M.F. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest., 2003, 112, 693-706.
51. Kobayashi, M.; Kweon, M.N.; Kuwata, H.; Schreiber, R.D.; Kiyono, H.; Takeda, K.; Akira, S. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J. Clin. Invest., 2003, 111, 1297-1308.
52. Duerr, R.H.; Taylor, K.D.; Brant, S.R.; Rioux, J.D.; Silverberg, M.S.; Daly, M.J.; Steinhart, A.H.; Abraham, C.; Regueiro, M.; Griffiths, A.; Dassopoulos, T.; Bitton, A.; Yang, H.; Targan, S.; Datta, L.W.; Kistner, E.O.; Schumm, L.P.; Lee, A.T.; Gregersen, P.K.; Barmada, M.M.; Rotter, J.I.; Nicolae, D.L.; Cho, J.H. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science, 2006, 314, 1461-1463.
53. Glocker, E.O.; Kotlarz, D.; Boztug, K.; Gertz, E.M.; Schäffer, A.A.; Noyan, F.; Perro, M.; Diestelhorst, J.; Allroth, A.; Murugan, D.; Hätscher, N.; Pfeifer, D.; Sykora, K.W.; Sauer, M.; Kreipe, H.; Lacher, M.; Nustede, R.; Woellner, C.; Baumann, U.; Salzer, U.; Koletzko, S.; Shah, N.; Segal, A.W.; Sauerbrey, A.; Buderus, S.; Snapper, S.B.; Grimbacher, B.; Klein, C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med., 2009, 361, 2033-2045.
54. Ogura, Y.; Bonen, D.K.; Inohara, N.; Nicolae, D.L.; Chen, F.F.; Ramos, R.; Britton, H.; Moran, T.; Karaliuskas, R.; Duerr, R.H.; Achkar, J.P.; Brant, S.R.; Bayless, T.M.; Kirschner, B.S.; Hanauer, S.B.; Nuñez, G.; Cho, J.H. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 2001, 411, 603-606.
55. Hugot, J.P.; Chamaillard, M.; Zouali, H.; Lesage, S.; Cézard, J.P.; Belaiche, J.; Almer, S.; Tysk, C.; O'Morain, C.A.; Gassull, M.; Binder, V.; Finkel, Y.; Cortot, A.; Modigliani, R.; Laurent-Puig, P.; Gower-Rousseau, C.; Macry, J.; Colombel, J.F.; Sahbatou, M.; Thomas, G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 2001, 411, 599-603.
56. Cooney, R.; Baker, J.; Brain, O.; Danis, B.; Pichulik, T.; Allan, P.; Ferguson, D.J.; Campbell, B.J.; Jewell, D.; Simmons, A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat. Med., 2010, 16, 90-97.
57. Heller, F.; Fuss, I.J.; Nieuwenhuis, E.E.; Blumberg, R.S.; Strober, W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity, 2002, 17, 629-638.
58. Strober, W.; Fuss, I.J. Pro-inflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology, 2011; 140, 1756-1767.
59. Fisher, S.A.; Tremelling, M.; Anderson, C.A.; Gwilliam, R.; Bumpstead, S.; Prescott, N.J.; Nimmo, E.R.; Massey, D.; Berzuini, C.; Johnson, C.; Barrett, J.C.; Cummings, F.R.; Drummond, H.; Lees, C.W.; Onnie, C.M.; Hanson, C.E.; Blaszczyk, K.; Inouye, M.; Ewels, P.; Ravindrarajah, R.; Keniry, A.; Hunt, S.; Carter, M.; Watkins, N.; Ouwehand, W.; Lewis, C.M.; Cardon, L.; Lobo, A.; Forbes, A.; Sanderson, J.; Jewell, D.P.; Mansfield, J.C.; Deloukas, P.; Mathew, C.G.; Parkes, M.; Satsangi, J. Wellcome Trust Case Control Consortium. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat. Genet., 2008, 40, 710-712.
60. UK IBD Genetics Consortium; Barrett, J.C.; Lee, J.C.; Lees, C.W.; Prescott, N.J.; Anderson, C.A.; Phillips, A.; Wesley, E.; Parnell, K.; Zhang, H.; Drummond, H.; Nimmo, E.R.; Massey, D.; Blaszczyk, K.; Elliott, T.; Cotterill, L.; Dallal, H.; Lobo, A.J.; Mowat, C.; Sanderson, J.D.; Jewell, D.P.; Newman, WG.; Edwards, C.; Ahmad, T.; Mansfield, J.C.; Satsangi, J.; Parkes, M.; Mathew, C.G.; Donnelly, P.; Peltonen, L.; Blackwell, J.M.; Bramon, E.; Brown, M.A.; Casas, J.P.; Corvin, A.; Craddock, N.; Deloukas, P.; Duncanson, A.; Jankowski, J.; Markus, H.S.; Mathew, C.G.; McCarthy, M.I.; Palmer, C.N.; Plomin, R.; Rautanen, A.; Sawcer, S.J.; Samani, N.; Trembath, R.C.; Viswanathan, A.C.; Wood, N.; Spencer, C.C.; Barrett, J.C.; Bellenguez, C.; Davison, D.; Freeman, C.; Strange, A.; Donnelly, P.; Langford, C.; Hunt, S.E.; Edkins, S.; Gwilliam, R.; Blackburn, H.; Bumpstead, S.J.; Dronov, S.; Gillman, M.; Gray, E.; Hammond, N.; Jayakumar, A.; McCann, O.T.; Liddle, J.; Perez, M.L.; Potter, S.C.; Ravindrarajah, R.; Ricketts, M.; Waller, M.; Weston, P.; Widaa, S.; Whittaker, P.; Deloukas, P.; Peltonen, L.; Mathew, C.G.; Blackwell, J.M.; Brown, M.A.; Corvin, A.; McCarthy, M.I.; Spencer, C.C.; Attwood, A.P.; Stephens, J.; Sambrook, J.; Ouwehand, W.H.; McArdle, W.L.; Ring, S.M.; Strachan, D.P. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat. Genet., 2009, 41, 1330-1334.
61. Ahn, S.H.; Shah, Y.M.; Inoue, J.; Morimura, K.; Kim, I.; Yim, S.; Lambert, G.; Kurotani, R.; Nagashima, K.; Gonzalez, F.J.; Inoue, Y. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm. Bowel Dis., 2008, 14, 908-920.
62. Noble, C.L.; Abbas, A.R.; Cornelius, J.; Lees, C.W.; Ho, G.T.; Toy, K.; Modrusan, Z.; Pal, N.; Zhong, F.; Chalasani, S.; Clark, H.; Arnott, I.D.; Penman, I.D.; Satsangi, J.; Diehl, L. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut, 2008, 57, 1398-1405.
63. McGovern, D.P.; Taylor, K.D.; Landers, C.; Derkowski, C.; Dutridge, D.; Dubinsky, M.; Ippoliti, A.; Vasiliauskas, E.; Mei, L.; Mengesha, E.; King, L.; Pressman, S.; Targan, S.R.; Rotter, J.I. MAGI2 genetic variation and inflammatory bowel disease. Inflamm. Bowel Dis., 2009, 15, 75-83.
64. Hermiston, M.L.; Gordon, J.I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science, 1995, 270, 1203-1207.
65. Wu, S.; Rhee, K.J.; Zhang, M.; Franco, A.; Sears, C.L. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage. J. Cell Sci., 2007, 120, 1944-51942.
66. Teller, I.C.; Beaulieu, J.F. Interactions between laminin and epithelial cells in intestinal health and disease. Expert Rev. Mol. Med., 2001, 3, 1-18.
67. Seksik, P. Gut microbiota and IBD. Gastroenterol. Clin. Biol., 2010, 34(Suppl 1), S44-51.
68. Garrett, W.S.; Lord, G.M.; Punit, S.; Lugo-Villarino, G.; Mazmanian, S.K.; Ito, S.; Glickman, J.N.; Glimcher, L.H. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell, 2007, 131, 33-45.
69. Elson, C.O.; Sartor, R.B.; Tennyson, G.S.; Riddell, R.H. Experimental models of inflammatory bowel disease. Gastroenterology, 1995, 109, 1344-1367.
70. Rosen, M.J.; Frey, M.R.; Washington, M.K.; Chaturvedi, R.; Kuhnhein, L.A.; Matta, P.; Revetta, F.L.; Wilson, K.T.; Polk, D.B. STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. Inflamm. Bowel Dis., Feb 9, 2011, [Epub Ahead of Print].
71. Colombel, J.F.; Lémann, M.; Cassagnou, M.; Bouhnik, Y.; Duclos, B.; Dupas, J.L.; Notteghem, B.; Mary, J.Y. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am. J. Gastroenterol., 1999, 94, 674-678.
72. Van Kruiningen, H.J.; Colombel, J.F. The forgotten role of lymphangitis in Crohn's disease. Gut, 2008, 57, 1-4.
73. Kalima, T.V.; Saloniemi, H.; Rahko, T. Experimental regional enteritis in pigs. Scand. J. Gastroenterol., 1976, 11, 353-362.
74. Demas, G.E. The energetics of immunity: a neuroendocrine link between energy balance and immune function. Horm. Behav., 2004, 45, 173-180.
75. Batra, A.; Stroh, T.; Siegmund, B. Extraluminal factors contributing to inflammatory bowel disease. World J. Gastroenterol., 2011, 17, 572-577.
76. Colombel, J.F.; Solem, C.A.; Sandborn, W.J.; Booya, F.; Loftus, E.V.Jr., Harmsen, W.S.; Zinsmeister, A.R.; Bodily, K.D.; Fletcher, J.G. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut, 2006, 55, 1561-1567.
77. Batra A, Zeitz M, Siegmund B. Adipokine signaling in inflammatory bowel disease. Inflamm. Bowel Dis., 2009, 15, 1897-905.
78. Batra, A.; Okur, B.; Glauben, R.; Erben, U.; Ihbe, J.; Stroh, T.; Fedke, I.; Chang, H.D.; Zeitz, M.; Siegmund, B. Leptin: a critical regulator of CD4+ T-cell polarization in vitro and in vivo. Endocrinology, 2010, 151, 56-62.
79. Cadwell, K.; Liu, J.Y.; Brown, S.L.; Miyoshi, H.; Loh, J.; Lennerz, J.K.; Kishi, C.; Kc, W.; Carrero, J.A.; Hunt, S.; Stone, C.D.; Brunt, E.M.; Xavier, R.J.; Sleckman, B.P.; Li, E.; Mizushima, N.; Stappenbeck, T.S.; Virgin, H.W. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature, 2008, 456, 259-263.
80. Vasiliauskas, E.A.; Kam, L.Y.; Karp, L.C.; Gaiennie, J.; Yang, H.; Targan, S.R. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut, 2000, 47, 487-496.
81. Holtmann, M.H.; Krummenauer, F.; Claas, C.; Kremeyer, K.; Lorenz, D.; Rainer, O.; Vogel, I.; Böcker, U.; Böhm, S.; Büning, C.; Duchmann, R.; Gerken, G.; Herfarth, H.; Lügering, N.; Kruis, W.; Reinshagen, M.; Schmidt, J.; Stallmach, A.; Stein, J.; Sturm, A.; Galle, P.R.; Hommes, D.W.; D'Haens, G.; Rutgeerts, P.; Neurath, M.F. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig. Dis. Sci., 2006, 51, 1516-1524.
82. Watermanm M.; Xum W.; Stempakm J.M.; Milgromm R.; Bernsteinm C.N.; Griffithsm A.M.; Greenbergm G.R.; Steinhartm A.H.; Silverbergm M.S. Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: Correlations with pathogenesis. Inflamm. Bowel. Dis., Dec 10, 2010, [Epub Ahead of Print].
83. Stremmel, W.; Ehehalt, R.; Autschbach, F.; Karner, M. Phosphatidylcholine for steroid- refractory chronic ulcerative colitis: a randomized trial. Ann. Intern. Med., 2007, 147, 603-610.
84. Saber, R.; Zadeh, M.; Pakanati, K.C.; Bere, P.; Klaenhammer, T.; Mohamadzadeh, M. Lipoteichoic acid-deficient Lactobacillus acidophilus regulates downstream signals. Immunotherapy, 2011, 3, 337-347.
85. Arijs, I.; Li, K.; Toedter, G.; Quintens, R.; Van Lommel, L.; Van Steen, K.; Leemans, P.; De Hertogh, G.; Lemaire, K.; Ferrante, M.; Schnitzler, F.; Thorrez, L.; Ma, K.; Song, X.Y.; Marano, C.; Van Assche, G.; Vermeire, S.; Geboes, K.; Schuit, F.; Baribaud, F.; Rutgeerts, P. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut, 2009, 58, 1612-1619.